The holy grail of new drug development: India continues to grapple with the challenges of new drug development

Abstract

The announcement by Zydus Cadila in early June that their new drug to treat diabetics who also suffer from high cholesterol has passed all stages of clinical trials is an important landmark for the Indian pharmaceutical industry. This is not the first new chemical entity (NCE) developed by an Indian company. Ranbaxy, DRL, and Biocon are some of the companies that developed NCEs earlier. But none of these NCEs reached the market (so far), mainly due to hiccups faced at one of the later stages of trials. Read more at: https://www.thehindubusinessline.com/news/variety/the-holy-grail-of-new-drug-development/article23031250.ece